Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics (APGE) to $110 from $95 and keeps a Buy rating on the shares to reflect recent pipeline advancements. The firm, which notes it has a “bullish view” on Apogee’s approach, looks forward to learning more about the company’s development plans at Apogee’s R&D Day on Monday, December 2, the analyst added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APGE:
- Apogee initiated with a Buy at Canaccord on APG777 ‘blockbuster potential’
- Apogee Therapeutics initiated with a Buy at Canaccord
- Apogee Therapeutics Highlights Pipeline Progress and Financials
- Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
- Apogee Therapeutics, Inc. (APGE) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
